Literature DB >> 33421362

The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation.

Bing Wu1, Song Zhang1, Zengli Guo1, Yanmin Bi2, Mingxia Zhou1, Ping Li1, Maryamsadat Seyedsadr3, Xiaojiang Xu4, Jian-Liang Li4, Silva Markovic-Plese3, Yisong Y Wan5.   

Abstract

Th17 cells are known to exert pathogenic and non-pathogenic functions. Although the cytokine transforming growth factor β1 (TGF-β1) is instrumental for Th17 cell differentiation, it is dispensable for generation of pathogenic Th17 cells. Here, we examined the T cell-intrinsic role of Activin-A, a TGF-β superfamily member closely related to TGF-β1, in pathogenic Th17 cell differentiation. Activin-A expression was increased in individuals with relapsing-remitting multiple sclerosis and in mice with experimental autoimmune encephalomyelitis. Stimulation with interleukin-6 and Activin-A induced a molecular program that mirrored that of pathogenic Th17 cells and was inhibited by blocking Activin-A signaling. Genetic disruption of Activin-A and its receptor ALK4 in T cells impaired pathogenic Th17 cell differentiation in vitro and in vivo. Mechanistically, extracellular-signal-regulated kinase (ERK) phosphorylation, which was essential for pathogenic Th17 cell differentiation, was suppressed by TGF-β1-ALK5 but not Activin-A-ALK4 signaling. Thus, Activin-A drives pathogenic Th17 cell differentiation, implicating the Activin-A-ALK4-ERK axis as a therapeutic target for Th17 cell-related diseases.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALK4; ALK5; Activin-A; EAE; ERK1/2; TGF-β1; autoimmune disease; multiple sclerosis; pathogenic Th17 cells

Mesh:

Substances:

Year:  2021        PMID: 33421362      PMCID: PMC7878438          DOI: 10.1016/j.immuni.2020.12.010

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  59 in total

Review 1.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 2.  The dichotomous nature of T helper 17 cells.

Authors:  Brigitta Stockinger; Sara Omenetti
Journal:  Nat Rev Immunol       Date:  2017-05-30       Impact factor: 53.106

3.  CRISPR-Cas9 knockin mice for genome editing and cancer modeling.

Authors:  Randall J Platt; Sidi Chen; Yang Zhou; Michael J Yim; Lukasz Swiech; Hannah R Kempton; James E Dahlman; Oren Parnas; Thomas M Eisenhaure; Marko Jovanovic; Daniel B Graham; Siddharth Jhunjhunwala; Matthias Heidenreich; Ramnik J Xavier; Robert Langer; Daniel G Anderson; Nir Hacohen; Aviv Regev; Guoping Feng; Phillip A Sharp; Feng Zhang
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

Review 4.  The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis.

Authors:  M P Hedger; D M de Kretser
Journal:  Cytokine Growth Factor Rev       Date:  2013-03-29       Impact factor: 7.638

Review 5.  Antagonists of activin signaling: mechanisms and potential biological applications.

Authors:  Craig A Harrison; Peter C Gray; Wylie W Vale; David M Robertson
Journal:  Trends Endocrinol Metab       Date:  2005-03       Impact factor: 12.015

Review 6.  Transforming Growth Factor-β Signaling in Immunity and Cancer.

Authors:  Eduard Batlle; Joan Massagué
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

7.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

8.  Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease.

Authors:  Corinna F Brereton; Caroline E Sutton; Stephen J Lalor; Ed C Lavelle; Kingston H G Mills
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

9.  Characterization of type I receptors for transforming growth factor-beta and activin.

Authors:  P ten Dijke; H Yamashita; H Ichijo; P Franzén; M Laiho; K Miyazono; C H Heldin
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

10.  Reversing SKI-SMAD4-mediated suppression is essential for TH17 cell differentiation.

Authors:  Song Zhang; Motoki Takaku; Liyun Zou; Ai-di Gu; Wei-Chun Chou; Ge Zhang; Bing Wu; Qing Kong; Seddon Y Thomas; Jonathan S Serody; Xian Chen; Xiaojiang Xu; Paul A Wade; Donald N Cook; Jenny P Y Ting; Yisong Y Wan
Journal:  Nature       Date:  2017-10-25       Impact factor: 49.962

View more
  8 in total

Review 1.  RORγt protein modifications and IL-17-mediated inflammation.

Authors:  Ritesh Kumar; Arianne L Theiss; K Venuprasad
Journal:  Trends Immunol       Date:  2021-10-09       Impact factor: 16.687

Review 2.  Different Immunoregulation Roles of Activin A Compared With TGF-β.

Authors:  Fanglin Li; Yiru Long; Xiaolu Yu; Yongliang Tong; Likun Gong
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

3.  RORγt phosphorylation protects against T cell-mediated inflammation.

Authors:  Shengyun Ma; Shefali A Patel; Yohei Abe; Nicholas Chen; Parth R Patel; Benjamin S Cho; Nazia Abbasi; Suling Zeng; Bernd Schnabl; John T Chang; Wendy Jia Men Huang
Journal:  Cell Rep       Date:  2022-03-15       Impact factor: 9.423

Review 4.  Th17 cells and inflammation in neurological disorders: Possible mechanisms of action.

Authors:  Yajun Shi; Bin Wei; Lingjun Li; Bin Wang; Miao Sun
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

5.  Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas.

Authors:  J J Staudacher; Alexander Arnold; A A Kühl; M Pötzsch; S Daum; M Winterfeld; E Berg; M Hummel; B Rau; U Stein; C Treese
Journal:  BMC Cancer       Date:  2022-09-05       Impact factor: 4.638

6.  Histone deacetylase 1 and 3 inhibitors alleviate colon inflammation by inhibiting Th17 cell differentiation.

Authors:  Zhengrong Gu; Xiaotian Chen; Dandan Zhu; Songting Wu; Chenggong Yu
Journal:  J Clin Lab Anal       Date:  2022-09-15       Impact factor: 3.124

7.  The LncRNA AK018453 regulates TRAP1/Smad signaling in IL-17-activated astrocytes: A potential role in EAE pathogenesis.

Authors:  Qingxiu Zhang; Ying Yang; Yingyu Chen; Yifan Wang; Suping Qin; Ruixue Lv; Menglu Zhou; Qian Yu; Xiangyang Li; Xiaocui Li; Xiaotian Wang; Hongjuan You; Yugang Wang; Feng Zhou; Xiaomei Liu
Journal:  Glia       Date:  2022-07-02       Impact factor: 8.073

8.  SKI Expression Suppresses Pathogenic Th17 Cell Response and Mitigates Experimental Autoimmune Encephalomyelitis.

Authors:  Ping Li; Zengli Guo; Yisong Y Wan
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.